Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences


Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences:

June 18, 2019 at 3:00 p.m. ET ? Raymond James Life Sciences and MedTech Conference, New York City
June 19, 2019 at 9:30 a.m. ET ? JMP Securities Life Sciences Conference, New York City

A live webcast of the presentations will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at www.enanta.com. A replay of the webcasts will be available following the presentation and will be archived for approximately 30 days.

About Enanta

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta's research and development efforts are currently focused on the following disease targets: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), and hepatitis B virus (HBV).

Enanta's research and development activities are funded by royalties from HCV products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is now sold by AbbVie in numerous countries as part of its newest treatment for chronic hepatitis C virus (HCV) infection. This leading HCV regimen is sold under the tradenames MAVYRETtm (U.S.) and MAVIRETtm (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.


These press releases may also interest you

at 10:45
The "PCR Markets. Forecasts for qPCR, dPCR, Singleplex & Multiplex Markets and by Application, Product and Place. With Executive and Consultant Guides, Including Customized Forecasting and Analysis. 2023 to 2027" report has been added to...

at 10:45
Fluency, the leading innovator of digital advertising management and automation solutions for agencies and large enterprises, announced today that it earned the number one ranking in the small business category...

at 10:31
Gulfstream Aerospace Corp., a wholly owned subsidiary of General Dynamics , today announced the all-new Gulfstream G700 has received Federal Aviation Administration (FAA) type certification, paving the way for customer deliveries of the most spacious...

at 10:30
The "Licensing Deals in Biotechnology 2019-2024" report has been added to ResearchAndMarkets.com's offering. Licensing Deals in Biotechnology provides a detailed understanding and analysis of how and why companies enter licensing deals. Fully...

at 10:30
The "Molecular Diagnostics for Cancer: Markets Forecasts by Cancer Type, Product, and Place with Executive & Consultant Guides and Customization. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering. Exciting technical...

at 10:30
RIVANNA®, a developer of imaging-based medical solutions, names Craig Loomis as senior director of product management. With over 25 years of extensive experience in global product development and commercialization within the healthcare sector, Mr....



News published on and distributed by: